Right now is an exciting time for vaccine science, with an unprecedented level of attention, resources, and testing being directed at the effort to control the COVID-19 pandemic. In this post, we share a new video and provide additional information to explain the role that InVitria’s recombinant human protein products play in accelerating the vaccine development timeline.
While we fight SARS-CoV-2, we must not turn our back on influenza
As of this writing, the SARS-CoV-2 virus has infected at least 15.5 million people worldwide and resulted in at least 632,000 deaths. While extreme public health measures such as testing, contact tracing, school closures, travel restrictions, stay-at-home orders, social distancing, and compulsory masking, appear to have tamed the spread of the virus in some parts of the world, the pandemic is still growing in a number of highly populated countries including the US and Brazil, and outbreaks are frequent everywhere as countries try to balance the risks of the virus against the very real risks of economic and mental health collapse.
Accordingly, a huge global effort is under way to develop vaccines that will provide widespread immunity against the virus, relieve the burden of COVID-19 morbidity and mortality, and allow communities to return to more sustainable social and economic behaviors.
In the US, a cooperative partnership between the CDC, the FDA, the NIH, BARDA, the DoD, private industry, and other federal agencies—known as Operation Warp Speed (OWS) -- is coordinating a massive effort to develop, test, approve, and deliver a safe and effective vaccine to US citizens by early 2021. Although that is an incredibly aggressive timeline for vaccine development, several candidates have shown promise in early testing and are poised to move into pivotal trials. No matter how long the effort takes, the research being done is sure to advance vaccine science in a paradigm-shifting way.
High-Performance Production of Viral Vectors for Cell and Gene Therapy Using OptiPEAK HEK293t Complete Media
Posted By Jeanne McAdara Ph.D. on 6/24/20 9:33 AM
HEK293t cells are an indispensable tool for the production of the viral vectors at the heart of cell and gene therapy technology. To introduce a way to improve performance, consistency, and safety of your HEK293-based production InVitria’s team released a new video that talks about our serum-free chemically defined media product, OptiPEAK HEK293t Complete Media.
Recombinant Virus Platforms are Out in Front in the Race to Develop Vaccines Against SARS-CoV-2 and COVID-19 Disease
Posted By Jeanne McAdara Ph.D. on 6/12/20 8:00 AM
SARS-CoV-2 continues to circulate the globe, causing widespread illness, loss of life , and far-reaching societal and economic disruption. Public health measures like stay-at-home and safer-at-home have been successful in checking the virus’s geometric growth curve, and treatments are in development. However, epidemiologists generally agree that achieving “herd immunity” through a safe and effective vaccine is indispensable to overcoming this challenge to humanity’s social, mental, and economic health and wellbeing.
Cellastim S Recombinant Human Serum Albumin in the Generation of Functional Cardiomyocytes from Pluripotent Stem Cells
Posted By Jeanne McAdara Ph.D. on 5/9/19 11:00 AM
The number and breadth of applications for induced human embryonic and pluripotent stem cells (hi-ESCs and hi-PSCs) in both research and clinical settings continue to co-evolve with our understanding of how to harness them as biological tools.